BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31500970)

  • 1. Measles and rubella immunity in the population of Bhutan, 2017.
    Wangchuk S; Nogareda F; Tshering N; Khandu L; Pelden S; Wannemuehler K; Wangdi S; Wangchuk U; Mulders M; Tamang T; Patel MK
    Vaccine; 2019 Oct; 37(43):6463-6469. PubMed ID: 31500970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of nationwide supplementary immunization in Lao People's Democratic Republic: Population-based seroprevalence survey of anti-measles and anti-rubella IgG in children and adults, mathematical modelling and a stability testing of the vaccine.
    Hachiya M; Miyano S; Mori Y; Vynnycky E; Keungsaneth P; Vongphrachanh P; Xeuatvongsa A; Sisouk T; Som-Oulay V; Khamphaphongphane B; Sengkeopaseuth B; Pathammavong C; Phounphenghak K; Kitamura T; Takeda M; Komase K
    PLoS One; 2018; 13(3):e0194931. PubMed ID: 29596472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-specific prevalence of IgG against measles/rubella and the impact of routine and supplementary immunization activities: A multistage random cluster sampling study with mathematical modelling.
    Hachiya M; Vynnycky E; Mori Y; Do HT; Huynh MK; Trinh LH; Nguyen DD; Tran NAT; Hoang TT; Hoang HHT; Vo NDT; Le TH; Ichimura Y; Miyano S; Okawa S; Thandar MM; Yokobori Y; Inoue Y; Mizoue T; Takeda M; Komada K
    Int J Infect Dis; 2024 Jul; 144():107053. PubMed ID: 38641317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of measles and rubella antibodies in pregnant women Haiti, 2012.
    Fitter DL; Anselme R; Paluku G; Rey G; Flannery B; Tohme RA; Marston BJ; Griswold M; Boncy J; Vertefeuille JF
    Vaccine; 2013 Dec; 32(1):69-73. PubMed ID: 24188751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of measles and rubella vaccination one year after the nationwide campaign in Shiraz, Iran.
    Pourabbas B; Ziyaeyan M; Alborzi A; Mardaneh J
    Int J Infect Dis; 2008 Jan; 12(1):43-6. PubMed ID: 17950020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles and rubella IgG seroprevalence in persons 6 month-35 years of age, Mongolia, 2016.
    Nogareda F; Gunregjav N; Sarankhuu A; Munkhbat E; Ichinnorov E; Nymadawa P; Wannemuehler K; Mulders MN; Hagan J; Patel MK
    Vaccine; 2020 May; 38(26):4200-4208. PubMed ID: 32381479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
    Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
    PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey.
    Hayford K; Mutembo S; Carcelen A; Matakala HK; Munachoonga P; Winter A; Wanyiri JW; Searle K; Mwansa FD; Mwiche A; Phiri C; Book C; Thuma PE; Moss WJ
    Vaccine; 2019 Apr; 37(17):2387-2393. PubMed ID: 30905529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a Measles and Rubella Vaccination Campaign on Seroprevalence in Southern Province, Zambia.
    Carcelen AC; Mutembo S; Matakala KH; Chilumba I; Mulundu G; Monze M; Mwansa FD; Moss WJ; Hayford K
    Am J Trop Med Hyg; 2021 May; 104(6):2229-2232. PubMed ID: 33939639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran.
    Saffar H; Khalifeloo M; Saffar MJ; Abdollahi A; Parsaei MR; Ghorbani GR; Salarvand S; Aarabi M
    BMC Infect Dis; 2021 Mar; 21(1):305. PubMed ID: 33765968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial.
    Kohler KA; Suleiman AJ; Robertson SE; Malankar P; Al-Khusaiby S; Helfand RF; Brown D; Bellini WJ; Sutter RW
    J Infect Dis; 2003 May; 187 Suppl 1():S177-85. PubMed ID: 12721911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haiti 2007-2008 national measles-rubella vaccination campaign: implications for rubella elimination.
    Rainey JJ; Danovaro-Holliday MC; Magloire R; Kananda G; Lee CE; Chamouillet H; Lacapere F; Mung K; Luman ET
    J Infect Dis; 2011 Sep; 204 Suppl 2():S616-21. PubMed ID: 21954256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016.
    Subaiya S; Tabu C; N'ganga J; Awes AA; Sergon K; Cosmas L; Styczynski A; Thuo S; Lebo E; Kaiser R; Perry R; Ademba P; Kretsinger K; Onuekwusi I; Gary H; Scobie HM
    PLoS One; 2018; 13(7):e0199786. PubMed ID: 29965975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.
    Murhekar MV; Gupta N; Hasan AZ; Kumar MS; Kumar VS; Prosperi C; Sapkal GN; Thangaraj JWV; Kaduskar O; Bhatt V; Deshpande GR; Thankappan UP; Bansal AK; Chauhan SL; Grover GS; Jain AK; Kulkarni RN; Sharma SK; Chaaithanya IK; Kharwal S; Mishra SK; Salvi NR; Sharma S; Sarmah NP; Sabarinathan R; Duraiswamy A; Rani DS; Kanagasabai K; Lachyan A; Gawali P; Kapoor M; Shrivastava AK; Chonker SK; Tilekar B; Tandale BV; Ahmad M; Sangal L; Winter A; Mehendale SM; Moss WJ; Hayford K
    Lancet Glob Health; 2022 Nov; 10(11):e1655-e1664. PubMed ID: 36240831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Australian rubella serosurvey 2012-2013: On track for elimination?
    Edirisuriya C; Beard FH; Hendry AJ; Dey A; Gidding HF; Hueston L; Dwyer DE; Wood JG; Macartney KK; McIntyre PB
    Vaccine; 2018 May; 36(20):2794-2798. PubMed ID: 29661586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating Blood Collection within Household Surveys: Lessons Learned from Nesting a Measles and Rubella Serological Survey within a Post-Campaign Coverage Evaluation Survey in Southern Province, Zambia.
    Mutembo S; Carcelen A; Mwansa FD; Searle K; Wanyiri JW; Book C; Thuma PE; Moss WJ; Hayford K
    Am J Trop Med Hyg; 2018 Dec; 99(6):1639-1642. PubMed ID: 30277204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign.
    Honarvar B; Moghadami M; Moattari A; Emami A; Odoomi N; Bagheri Lankarani K
    PLoS One; 2013; 8(1):e55043. PubMed ID: 23383049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.